Evidence map›Paper›PMID 30144465›Full record

ReviewToxicology2018

Neurotoxicity in acute and repeated organophosphate exposure.

Sean X Naughton, Alvin V Terry

Registry-linked trialAbstract readReview
In one paragraph

Review in Toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06021262 (Assessment of the Prognostic Value of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity), which is not on this map. Cited by 119 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 3 pooled it
29.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06021262 unknown statusnot on this mapstarted 2023, after this paper: background citation

Assessment of the Prognostic Value of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity

TypeobservationalSponsorAlexandria UniversityRan2023 to 2024Enrolled90ConditionsNeuroinflammatory Response, Nerve Injury, Nerve Damage, NeurotoxicityArmsexposure to organophosphates
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 323 citations in OpenAlex.

  1. A Systematic Review and Meta-analysis of Chemical Exposures and Attention-Deficit/Hyperactivity Disorder in Children.Prevention science : the official journal of the Society for Prevention Research · 2024
    Pooled it
  2. Pooled it
  3. Risk Factors for Brain Health in Agricultural Work: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  4. Fly · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Neurocognitive and neurobiological effects of low dose organophosphate exposure.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sean X NaughtonDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, 30912, Georgia.
Alvin V TerryDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, 30912, Georgia. Electronic address: aterry@augusta.edu.
Augusta University · US

Funding

Cholinesterase Inhibitors, Axonal Transport, and MemoryR01ES012241 · NIEHS · UNIVERSITY OF GEORGIA (UGA) · PI TERRY, ALVIN V · 2004 to 2013
$2.8M
NIEHS NIH HHS R01 ES012241
6 · The paper itself

Abstract

The term organophosphate (OP) refers to a diverse group of chemicals that are found in hundreds of products worldwide. As pesticides, their most common use, OPs are clearly beneficial for agricultural productivity and the control of deadly vector-borne illnesses. However, as a consequence of their widespread use, OPs are now among the most common synthetic chemicals detected in the environment as well as in animal and human tissues. This is an increasing environmental concern because many OPs are highly toxic and both accidental and intentional exposures to OPs resulting in deleterious health effects have been documented for decades. Some of these deleterious health effects include a variety of long-term neurological and psychiatric disturbances including impairments in attention, memory, and other domains of cognition. Moreover, some chronic illnesses that manifest these symptoms such as Gulf War Illness and Aerotoxic Syndrome have (at least in part) been attributed to OP exposure. In addition to acute acetylcholinesterase inhibition, OPs may affect a number of additional targets that lead to oxidative stress, axonal transport deficits, neuroinflammation, and autoimmunity. Some of these targets could be exploited for therapeutic purposes. The purpose of this review is thus to: 1) describe the important uses of organophosphate (OP)-based compounds worldwide, 2) provide an overview of the various risks and toxicology associated with OP exposure, particularly long-term neurologic and psychiatric symptoms, 3) discuss mechanisms of OP toxicity beyond cholinesterase inhibition, 4) review potential therapeutic strategies to reverse the acute toxicity and long term deleterious effects of OPs.

Indexed as

Agricultural Workers' DiseasesAnimalsAntidotesChemical TerrorismChemical Warfare AgentsCholinesterase InhibitorsDose-Response Relationship, DrugHumansNervous SystemNeurotoxicity SyndromesOccupational ExposureOrganophosphate PoisoningOrganophosphatesPersian Gulf SyndromePesticidesPrognosisAntidotesChemical Warfare AgentsCholinesterase InhibitorsOrganophosphatesPesticidesAerotoxic syndromeAgricultureCholinesterase inhibitorGulf war illnessMemoryPesticide

Identifiers

PMID30144465
PMCPMC6839762
OpenAlexW2888522738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.